Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.
about
Emotional and sexual concerns in women undergoing pelvic surgery and associated treatment for gynecologic cancerChemotherapy-induced peripheral neurotoxicity: a critical analysisVascularization of the dorsal root ganglia and peripheral nerve of the mouse: implications for chemical-induced peripheral sensory neuropathiesA randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trialsFactors associated with grade 3 or 4 treatment-related toxicity in women with advanced or recurrent cervical cancer: an exploratory analysis of NRG Oncology/Gynecologic Oncology Group trials 179 and 204.[EXPRESS] Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy; cause and effect?Persistent mobility disability after neurotoxic chemotherapyTrabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trialNociceptor beta II, delta, and epsilon isoforms of PKC differentially mediate paclitaxel-induced spontaneous and evoked pain.Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer.[Chemotherapy-induced peripheral neuropathies: an integrative review of the literature].Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin.Contemporary quality of life issues affecting gynecologic cancer survivors.An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the ratLimitations to the use of carboplatin-based therapy in advanced ovarian cancerChemotherapy-induced peripheral neuropathy: Current status and progress.Survivors of gynecologic malignancies: impact of treatment on health and well-beingPersistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristineQuality of life considerations in gynecologic cancer. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.Health-related quality of life in ovarian cancer patients and its impact on clinical managementSupportive care for women with gynecologic cancers.Treatment of recurrent epithelial ovarian cancerEvaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment.A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumorsLong-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review.Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge.The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer.Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignanciesEarly, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy.Bilateral Blindness Following Chemoradiation for Locally Advanced Oropharyngeal Carcinoma.Taxane-Induced Peripheral Neurotoxicity.Discussion: session 2.Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO AWhen nonplatinum is the answer: the role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer.Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial.Neuro- and nephroprotective effect of grape seed proanthocyanidin extract against carboplatin and thalidomide through modulation of inflammation, tumor suppressor protein p53, neurotransmitters, oxidative stress and histology.
P2860
Q26773707-DAB9DDA3-EDE5-4AA2-A0AC-2AE0D0BDD8F6Q27010318-ADB8B09B-543A-4287-9BC8-8CEC242F7C8BQ33324545-18E7C60E-5D8D-45E7-AB23-97631B05B6C0Q33387755-F1F3A2C8-4D27-47B2-A5C5-CBF813072972Q33409319-4AD413BA-BD22-4A53-82FF-160B2A5FF1F2Q33418750-067E3222-8C1F-48B3-A70E-653BAFF294ABQ33824948-E56B8C57-7ADB-4243-9BD0-0C6510E69F07Q34259315-E8C2B320-620F-4651-BE43-F77A6D2CFDC2Q34413664-84A2F174-798C-40B9-AFD7-CC26D02D129BQ35187458-F4282731-2145-4DC1-A5B6-75E605417C8EQ35210260-5095D1EA-A314-44AD-BA80-23C6FECF4D07Q35636254-8B1325DA-2B68-414E-B29E-932F59D12FFFQ35967152-9692E989-DBDA-466A-9EE5-028D4ECE3270Q36067725-1034E98B-C4CE-4121-AD38-1B73A50E4D6BQ36094403-59EB6DAC-69FF-4C44-919E-1DBB3DF416C1Q36382337-89E24A1B-0863-40DC-A445-C9D3BADCF02EQ36421901-19B74617-5925-442D-A0E8-FDD75464A87FQ36553964-1CF7CD2B-2EC3-4B6E-8494-DE56B3028117Q36636831-0922D6D4-3D19-4985-AC4A-0296FD2DD80CQ36679733-E5F08F13-382C-46AB-B609-5D0D37CD1E60Q37036780-FA4D340E-A4A4-4CCD-9CA7-9CC1C8159E3FQ37086010-F138FAAD-87BF-4D3E-A977-5CD8DFBCB3AAQ37224624-0A1C74A9-0E89-4308-8FF1-A43E064B552DQ37273523-0767BB32-20FB-4D78-BB15-719F401E7CAEQ37397508-17508B3D-0EF5-4C7A-9DC8-A84A7032D5FAQ37662576-CA388A1D-8A74-4167-B4D1-F918AE38BB8AQ38995032-461E2B12-94EC-4581-AF9F-6CFEDC36F34CQ39282981-820001F9-002B-4B14-9E1C-0D20438036F3Q41475920-6ED8C8FC-BEE3-4CE0-81C8-C37E0B991358Q42750577-7A20AA5E-3BF9-4956-B4FB-5428EEAB2F5CQ43164316-43322692-FE89-4768-A658-017E0A969A96Q45759415-4C4F7449-E3DD-4D6D-9F6F-7CC6DF99B040Q46190587-54679D75-4A9C-4056-83CB-1C3891924E8FQ47631494-3FC05B2F-172C-4579-9AAC-1F6EC2675DE2Q47903322-214099D2-60B1-4A4F-B678-1B78EDC004B5Q47979421-55BF3B03-C99F-420F-B07F-D25B4EDA05F6Q55018342-D87C5BBE-8EEB-4F88-A391-DE4291461A63
P2860
Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Residual neurotoxicity in ovar ...... r (MITO-4) retrospective study
@nl
Residual neurotoxicity in ovar ...... (MITO-4) retrospective study.
@ast
Residual neurotoxicity in ovar ...... (MITO-4) retrospective study.
@en
type
label
Residual neurotoxicity in ovar ...... r (MITO-4) retrospective study
@nl
Residual neurotoxicity in ovar ...... (MITO-4) retrospective study.
@ast
Residual neurotoxicity in ovar ...... (MITO-4) retrospective study.
@en
prefLabel
Residual neurotoxicity in ovar ...... r (MITO-4) retrospective study
@nl
Residual neurotoxicity in ovar ...... (MITO-4) retrospective study.
@ast
Residual neurotoxicity in ovar ...... (MITO-4) retrospective study.
@en
P2093
P2860
P921
P3181
P356
P1433
P1476
Residual neurotoxicity in ovar ...... (MITO-4) retrospective study.
@en
P2093
Alessandra Vernaglia Lombardi
Andrea de Matteis
Antonio Febbraro
Bruno Massidda
Carmela Pisano
Francesco Perrone
Giacomo Cartenì
Giampietro Gasparini
Giovanni Di Vagno
Giovanni Scambia
P2860
P2888
P3181
P356
10.1186/1471-2407-6-5
P407
P577
2006-01-07T00:00:00Z
P5875
P6179
1053639084